2024-514861-21-00招募中2 期
Deciphering IL-1 mediated inflammation for the targeted treatment of dilated cardiomyopathy.
Ospedale San Raffaele S.r.l.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年10月16日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Improvement in left-ventricular function, based on the increase of left ventricular (LV) ejection fraction (EF) assessed by transthoracic echocardiography at 4-weeks.
研究概览
简要总结
To evaluate the efficacy of IL-1 therapeutic blockade with Anakinra in improving Left Ventricular Ejection Fraction (LVEF) assessed by Trans Thoracic Echocardiograhy (TTE) at 4 weeks.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Age: 18 Years to 75 years;
- •Diagnosis of DCM according to current guidelines;
- •Symptoms of HF not improved or worsened despite at least 3 months of optimal therapy;
- •LVEF<50% at echocardiography (TTE), not improved or worsened despite at least 3 months of optimal therapy;
- •Increased high-sensitive troponin T (hs-TnT), and/or findings suggestive for actual or prior myocardial inflammation at cardiac MRI (within 6 months);
- •Absence of coronary artery disease (coronary artery stenosis > 50% at angiography or coronary CT Scan, acceptable if performed during the last 12 months).
- •Ability to sign an informed consent;
- •Presence of CD3+ >7/mm2 cells on EMB, in addiction to all the aformentioned inclusion criteria, will be needed exclusively to be enrollend in the Phase IIa Randomized Double Blind monocentric Clinical Trial.
排除标准
- •Genetic DCM;
- •Hepatic impairment = Child-Pugh Class C;
- •Mechanical ventilation circulatory assistance;
- •Pregnancy, breastfeeding. Female patients of childbearing potential may participate if adequate contraception is used during the study. (For the purposes of this trial, women of childbearing potential are defined as “All female subjects after puberty unless they are post-menopausal for at least 2 years or are surgically sterile.”)
- •Contra-indication to ANAKINRA (known hypersensitivity to the active substance or to any of the excipients or to Escherichia coli-derived proteins).
- •Presence of neutropenia < 1,5.109/L), or thrombocytopenia < 50.000/mm3;
- •Any comorbidity limiting survival or conditions predicting inability to complete the study;
- •Any concomitant immune-suppressive medications (i.e. azathioprine, methotrexate, cyclosporine, mycophenolate, cyclophosphamide, rituximab, tacrolimus);
- •Therapy with prednisone >10 mg daily and/or any immuno-suppressive agents within 3 months before the enrolment;
- •Congenital and/or acquired valvular disease or any other heart disease that could justify the severity of cardiac dysfunction; Major surgery within 2 weeks prior to randomization, or unhealed operation wounds.
- •Toxin abuse/exposure (Alcohol, amphetamines, cocaine, anthracyclines [e.g., doxycycline], trastuzumab, clozapine, chloroquine, carbon monoxide, cobalt, lead, mercury;
- •Clinical suspicion or proven underlying active, chronic or recurrent bacterial, fungal or viral infections, including tuberculosis, or HIV infection or epatitis B virus (HBV) or hepatitis C virus (HCV) infection, Lyme disease, Chagas disease or any other bacterial/fungeal/protozoal disease possibly responsible for DCM;
- •Endocrine, infiltrative (Cushing’s disease, acromegaly not clinically controlled hypo/hyperthyroidism, pheochromocytoma) or neuromuscular diseases (Dystrophinopathies [Duchenne/Becker muscular dystrophy/X-linked DCM], Limb-girdle muscular dystrophies, Facioscapulohumeral muscular dystrophy, Emery-Dreifuss muscular dystrophy, Friedreich’s ataxia, Myotonic dystrophy);
- •Contraindications to EMB;
- •Contraindications to PET/MRI (i.e. gadolinium hypersensitivity, renal failure, claustrophobia, pacemaker or ICD device, blood glucose>12.5 mmol/L);
- •History of malignancy in the previous 5 years. Exceptions are basal cell skin cancer, carcinoma-in-situ of the cervix or low-risk prostate cancer after curative therapy;
- •Any other concomitant or previous biological anti-cytokine treatment administered within 5 -half lives of the specific drug;
- •Renal failure as defined by estimated glomerular filtration rate (eGFR) <30 ml/min, according to Cockcroft-Gault;
结局指标
主要结局
Improvement in left-ventricular function, based on the increase of left ventricular (LV) ejection fraction (EF) assessed by transthoracic echocardiography at 4-weeks.
Improvement in left-ventricular function, based on the increase of left ventricular (LV) ejection fraction (EF) assessed by transthoracic echocardiography at 4-weeks.
次要结局
未报告次要终点
研究者
Giacomo De Luca
Scientific
Ospedale San Raffaele S.r.l.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Anakinra as prevention of fever and mucositis in patients with a stem cell transplantatioFebrile neutropenia and mucositisMedDRA version: 20.0Level: LLTClassification code 10028127Term: MucositisSystem Organ Class: 100000004867MedDRA version: 20.0Level: PTClassification code 10016288Term: Febrile neutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2018-005046-10-NLRadboud university medical center90
招募中
1 期
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic LeukemiaNCT07257640Zhejiang University20
招募中
2 期
Anakinra: safety and efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan - A randomized controlled trialand fever during neutropenia)mucositis and febrile neutropenia(inflammation of the lining of the digestive system100188651001796910005908NL-OMON48856Radboud Universitair Medisch Centrum90
招募中
2 期
Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)IgG4-related diseaseBehcet's disease2022-502968-20-02University Medical Center Utrecht60
进行中（未招募）
不适用
Anakinra to treat a gout attackEUCTR2014-000173-39-NLJan van Breemen Research Institute Reade and VU University Medical Centre